Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer

1988 ◽  
Vol 243 (2) ◽  
pp. 91-99 ◽  
Author(s):  
W. J�ger ◽  
R. Adam ◽  
L. Wildt ◽  
N. Lang
Keyword(s):  
Ovarian Cancer ◽  
Ca 125 ◽  
Line Treatment ◽  
Second Line ◽  
Second Look ◽  
Second Look Operation

Measurement of the ovarian cancer-associated antigen CA 125 prior to second look operation

1988 ◽  
Vol 24 (12) ◽  
pp. 1835-1837 ◽  
Author(s):  
Ole Mogensen ◽  
Bent Mogensen ◽  
Anders Jakobsen ◽  
Arne Sell
Keyword(s):  
Ovarian Cancer ◽  
Ca 125 ◽  
Second Look ◽  
Second Look Operation

The Biological Tumor Markers' Myopia: A Model with CA 125 and Second-look in Ovarian Cancer

1987 ◽  
Vol 2 (2) ◽  
pp. 105-108 ◽  
Author(s):  
Flavia Zanaboni ◽  
Giuseppe Accinell ◽  
Pietro Colombo ◽  
Giorgio Jelmoni ◽  
Cesare Morandi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Predictive Value ◽  
Disease Status ◽  
Residual Tumor ◽  
Tumor Burden ◽  
Epithelial Ovarian Carcinoma ◽  
Ca 125 ◽  
Biological Tumor Markers ◽  
Second Look ◽  
Second Look Operation

Preoperative CA 125 levels were measured in 36 patients with advanced epithelial ovarian carcinoma in clinical response undergoing a second-look operation. All the patients had positive levels (> 35 U/ml) of this tumor marker at diagnosis. The correlation between antigen levels and disease status at surgery revealed a sensitivity of this assay of 0.55 (only 11/20 patients still with tumor had positive levels) and a specificity of 0.94 (15/16 patients with no tumor had < 35 U/ml). The predictive value of a positive test was 0.92. This method unfortunately proved unable to recognize microscopic residual tumor burden, less than 0.5 cm.

The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer

1992 ◽  
Vol 46 (1) ◽  
pp. 29-32 ◽  
Author(s):  
H.H. Gallion ◽  
J.E. Hunter ◽  
J.R. van Nagell ◽  
H.E. Averette ◽  
J.M. Cain ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Stage Iii ◽  
Ca 125 ◽  
Second Look ◽  
Prognostic Implications ◽  
Second Look Operation ◽  
Low Serum

scholarly journals Assessing Type and Impact of Biases Potentially Occurring when Analyzing Real World Evidence: The Case of Second Line Treatment for Ovarian Cancer

2018 ◽  
Vol 21 ◽  
pp. S213
Author(s):  
F Kuehne ◽  
M Arvandi ◽  
LM Hess ◽  
DE Faries ◽  
R Matteucci Gothe ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Real World ◽  
Line Treatment ◽  
Second Line ◽  
Real World Evidence

Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer

2010 ◽  
Vol 20 (6) ◽  
pp. 953-957 ◽  
Author(s):  
Viviana Murgia ◽  
Roberto Sorio ◽  
Claudia Griso ◽  
Orazio Caffo ◽  
Carmela Arcuri ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Advanced Ovarian Cancer ◽  
Hematological Toxicity ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Platinum Resistant ◽  
Gynecology And Obstetrics

Objective:The aim of this phase 2 trial was to evaluate the tolerability and efficacy of combined gemcitabine (G) and epirubicin (E) as second-line treatment for patients with advanced ovarian cancer.Methods:Treatment with G 1000 mg/m2 (days 1 and 8) and E 60 mg/m2 (day 1) every 3 weeks for 3 or, in the absence of progression, 6 courses.Results:Fifty patients with advanced ovarian cancer (31 serous, 2 endometrioid, 10 unclassified adenocarcinoma, and 7 other) and a median age of 60 years (range, 38-74 years) were enrolled after giving their informed consent. Performance status according to the Eastern Cooperative Oncology Group was 0 in 29 patients (58%), 1 in 17 patients (34%), and 2 in 4 patients (8%), and the initial stages according to the International Federation of Gynecology and Obstetrics were I to II in 4 patients (8%), III in 31 patients (62%), and IV in 15 patients (30%). They had previously received a median of 1.5 lines of treatment (range, 1-4). The median platinum-free interval was 5 months (range, 0-12 months): 32 patients had relapse within 6 months and 18 patients had relapse after 6 months.The response rate was 42% (2% complete response and 40% partial response), with a median duration of 7.2 months: the corresponding figures were 37.5% and 5.2 months in the platinum-resistant patients and 50% and 8.8 months in the platinum-sensitive patients. The main grade 3 to 4 hematological toxicity was neutropenia (56% of cases). After a median follow-up of 13.5 months, median progression-free survival was 5 months, and median overall survival was 23.5 months.Conclusions:This E + G combination seems to be active and safe in platinum-resistant/refractory patients.

scholarly journals Evaluation of staging, cytoreduction and second-look operation of 119 ovarian cancer patients

1997 ◽  
Vol 115 (5) ◽  
pp. 1542-1547
Author(s):  
Eddie Fernando Candido Murta ◽  
Jurandyr Moreira de Andrade ◽  
Maurício Mesquita Sabino de Freitas ◽  
Sérgio Bighetti
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Study ◽  
Medical Records ◽  
Residual Disease ◽  
School Of Medicine ◽  
Second Look ◽  
Gynecology And Obstetrics ◽  
Data Source ◽  
Level Of Significance ◽  
Second Look Operation

OBJECTIVE:This study was conducted on patients with ovarian cancer in order to evaluate survival. DESIGN: A retrospective study of 119 cases of ovarian cancer from January 1977 to December 1992 with observation until 1993. LOCATION: Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, São Paulo University. PARTICIPANTS: Of the 119 cases, 70 (58.8%) presented epithelial carcinomas and 21 (17.6%) tumors of the sexual girdle/stroma. DATA SOURCE: The data were obtained from the medical records of the patients. MEASUREMENT: Statistical analysis of survival time was based on the nonparametric Mann-Whitney test with the level of significance set at P < 0.05. RESULTS: The patients with a negative second look had a mean survival of 79.4 ± 48.5 months versus 24.2 ± 15.1 months for patients with a positive second look (P < 0.02). CONCLUSIONS: It is concluded that patients with a negative second look present a better prognosis compared to those with residual disease.

Relation between CA125 levels and second-look operation for ovarian cancer

1997 ◽  
Author(s):  
H Nishimura ◽  
Y Kiyozuka ◽  
K Imamura ◽  
N Ohkura ◽  
F Murakami ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Second Look ◽  
Second Look Operation

Resection Guided by Antibodies (REGAJ) a Reappraisal after 10 Years

1998 ◽  
Vol 13 (4) ◽  
pp. 221-223 ◽  
Author(s):  
W. Jäger ◽  
S. Ackermann
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Retrospective Analysis ◽  
Ovarian Tumors ◽  
Murine Monoclonal Antibody ◽  
Ca 125 ◽  
Clinical Value ◽  
Second Look

Between 1986 and 1990 50 patients with ovarian cancer were submitted to a procedure which we called REGAJ - resection guided by antibodies. Using the radiolabeled murine monoclonal antibody OC 125, microscopic ovarian tumors producing CA 125 were detected during second-look surgery by a hand-held probe. Retrospective analysis after 10 years revealed that this procedure resulted in the cure of 4 of 11 patients, who would otherwise have been considered tumor free during second-look surgery and not further treated. Previous problems associated with the method can now be solved so that the clinical value of the procedure should be reconsidered.

Sign in / Sign up

Export Citation Format

Share Document